Patients with previously treated, unresectable, locally advanced or metastatic HER2+ breast cancer were treated with either tucatinib + trastuzumab + capecitabine or with placebo + trastuzumab + capecitabine. This evidence concerns the gene ERBB2 and breast cancer.